The smaller SPDR SP Biotech ETF (ARCA:XBI) has $576 million in total assets and is composed of 48 individual stocks. The ETF is up 25% in 2012 and is trading at a fresh all-time high. The top ten holdings make up 37% of the portfolio and the top two holdings are Human Genome Sciences (Nasdaq:HGSI) and Amylin Pharmaceuticals (Nasdaq:AMLN). HGSI is a recent takeover target and AMLN is up three-fold in the last six months. The expense ratio is Readmore >>






